Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Low Molecular Weight Heparin, Enoxaparin sodium, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial

Next Previous
Trial Profile

Low Molecular Weight Heparin, Enoxaparin sodium, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin (Primary) ; Enoxaparin sodium (Primary)
  • Indications Embolism and thrombosis; Preeclampsia
  • Focus Therapeutic Use
  • Acronyms HEPEPE; NOH-PE; NOHA

Most Recent Events

  • 01 Nov 2016 Results published in the Obstetrics and Gynecology
  • 06 Oct 2016 Primary endpoint has not been met. (The primary outcome is a composite morbidity that may occur : maternal death, or perinatal death, or preeclampsia, or abruptio placenta, or fetal growth restriction. [ Time Frame: from randomization until one month after the delivery ] [ Designated as safety issue: No ]), according to results published in the Obstetrics and Gynecology.
  • 06 Oct 2016 Results published in the Obstetrics and Gynecology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top